70-gene signature not cost-effective in breast cancer
(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in ...
Oct 18, 2014
0
0